CHEST 2021

Summaries of select sessions from the Chest 2021 Annual Meeting, held October 17 – 20, 2021.

Prompt Initiation of Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease Reduces Exacerbations

Presenter: Charlie Strange, MD

Triple therapy should be initiated promptly in patients with chronic obstruction pulmonary disease who have 1 severe or 2 moderate exacerbations to prevent further exacerbations.

Inhaled Treprostinil Effective in Many Groups of Patients with Pulmonary Hypertension

Presenter: Amber Meservey, MD

Inhaled treprostinil appears to be an effective therapy for patients with pulmonary hypertension of varying severity.

Idiopathic Pulmonary Hypertension-Related Hospitalizations Reduced Over 10 Years

Presenter: Bisharah Rizvi, MD

Idiopathic pulmonary artery hypertension-related hospitalizations and all-cause mortality related to hospitalization dropped dramatically from 2007 to 2017.

Hispanics and Blacks with COVID-19 More Likely to Suffer Severe Illness than Whites

Presenter: Anirudh Rao, MD

Hispanic and Black patients with COVID-19 have higher rates of hospitalization and mechanical ventilation than White patients.

Oral Treprostinil Improves Quality of Life in Patients with Pulmonary Arterial Hypertension

Presenter: Sandeep Sahay, MD

Patient-reported outcomes reveal that 6 months of oral treprostinil therapy improves quality of life in patients with pulmonary arterial hypertension.

Higher Doses of Inhaled Treprostinil Reduce Clinical Worsening in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Presenter: Aaron Waxman, MD

Data from the INCREASE study show that higher doses of inhaled treprostinil reduced rates of clinical worsening in patients with interstitial lung disease and associated pulmonary hypertension.

Inhaled Treprostinil Treats Pulmonary Hypertension Due to Interstitial Lung Disease

Presenter: Steven D. Nathan, MD

Treatment with inhaled treprostinil can improve exercise capacity and lower the risk of clinical worsening in patients with pulmonary hypertension due to interstitial lung disease.

Genomic Classifier Aids Diagnosis and Management of Interstitial Lung Disease

Presenter: Joseph A. Lasky, MD

A novel genomic classifier helps practitioners properly diagnose interstitial lung disease and select the most appropriate therapy.

Pulmonary Hypertension Due to Interstitial Lung Disease Increases Healthcare Use

Presenter: Gustavo A. Heresi, MD, MS

A real-world analysis using US claims data shows the burden of illness and healthcare costs increase in patients diagnosed with pulmonary hypertension due to interstitial lung disease.